Search Results - "Straka, RJ"

Refine Results
  1. 1

    Profile of Serum Bile Acids in Noncholestatic Volunteers: Gender-Related Differences in Response to Fenofibrate by Trottier, J, Caron, P, Straka, RJ, Barbier, O

    Published in Clinical pharmacology and therapeutics (01-08-2011)
    “…Fenofibrate belongs to the group of hypolipidemic fibrates that act as activators of the peroxisome proliferator–activated receptor‐α (PPARα), which is a…”
    Get full text
    Journal Article
  2. 2

    Preliminary evidence of genetic determinants of adiponectin response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network by Aslibekyan, S, An, P, Frazier-Wood, A.C, Kabagambe, E.K, Irvin, M.R, Straka, R.J, Tiwari, H.K, Tsai, M.Y, Hopkins, P.N, Borecki, I.B, Ordovas, J.M, Arnett, D.K

    “…Abstract Background and aims Adiponectin is an adipose-secreted protein that has been linked to changes in insulin sensitivity, high-density lipoprotein…”
    Get full text
    Journal Article
  3. 3

    Achieving Cholesterol Target in a Managed Care Organization (ACTION) Trial by Straka, Robert J., Taheri, Reza, Cooper, Susan L., Smith, James C.

    Published in Pharmacotherapy (01-03-2005)
    “…Study Objectives. To objectively compare the results of a collaborative approach using pharmacists with the results of usual care for achieving a low‐density…”
    Get full text
    Journal Article
  4. 4

    Discordance Between N-acetyltransferase 2 Phenotype and Genotype in a Population of Hmong Subjects by Straka, Robert J., Burkhardt, R. Todd, Lang, Nicholas P., Hadsall, Kelly Z., Tsai, Michael Y.

    Published in Journal of clinical pharmacology (01-07-2006)
    “…Polymorphisms of N‐acetyltransferase 2 (NAT2) acetylation may influence drug toxicities and efficacy and are associated with a differential susceptibility to…”
    Get full text
    Journal Article
  5. 5

    Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity by Matzke, Gary R., Frye, Reginald F., Early, John J., Straka, Robert J., Carson, Stanley W.

    Published in Pharmacotherapy (01-02-2000)
    “…Study Objective. To evaluate the metabolism of antipyrine, a general metabolic probe, caffeine, a probe for cytochrome P450 (CYP) 1A2 and N‐acetyltransferase…”
    Get full text
    Journal Article
  6. 6

    Patient Self-Reporting of Compliance Does Not Correspond with Electronic Monitoring: An Evaluation Using Isosorbide Dinitrate as a Model Drug by Straka, Robert J., Fish, Jeffrey T., Benson, Steven R., Suh, J. Thomas

    Published in Pharmacotherapy (01-01-1997)
    “…Study Objective. To assess the accuracy of patient‐kept diaries relative to electronic monitoring of compliance with isosorbide dinitrate prescribed 3…”
    Get full text
    Journal Article
  7. 7

    Assessment of Hypercholesterolemia Control in a Managed Care Organization by Straka, Robert J., Taheri, Reza, Cooper, Susan L., Tan, Agnes W. H., Smith, James C.

    Published in Pharmacotherapy (01-07-2001)
    “…To determine the extent of achievement of goal low‐density lipoprotein cholesterol (LDL) as defined by National Cholesterol Education Program—Adult Treatment…”
    Get full text
    Journal Article
  8. 8

    Revised NCEP Guidelines for the Management of Hypercholesterolemia: An Overview by Straka, Robert J

    Published in Formulary (Cleveland, Ohio) (01-02-2004)
    “…ATP III provides updated guidelines for the management of high blood cholesterol, taking into account recent advances in the literature supporting clinical…”
    Get full text
    Journal Article
  9. 9

    Calcium channel antagonists: morbidity and mortality--what's the evidence? by Straka, R J, Swanson, A L, Parra, D

    Published in American family physician (01-04-1998)
    “…Recent studies have shown an association between the use of calcium channel antagonists for the treatment of hypertension and an increased risk of myocardial…”
    Get full text
    Journal Article
  10. 10

    Chronopharmacologic considerations when treating the patient with hypertension: a review by Straka, R J, Benson, S R

    Published in Journal of clinical pharmacology (01-09-1996)
    “…Recognition of the existence of circadian variation in exacerbation of cardiovascular disease may have relevance to clinical use of cardioactive agents…”
    Get more information
    Journal Article
  11. 11

    Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota by Straka, R J, Hansen, S R, Walker, P F

    Published in Clinical pharmacology and therapeutics (01-07-1995)
    “…Genetic polymorphism of the P450IID6 (CYP2D6) enzyme system can be an important component of the variability in response to drug therapy. Interpopulation…”
    Get more information
    Journal Article
  12. 12

    Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease by Straka, R J, Fish, J T, Benson, S R, Suh, J T

    Published in Journal of clinical pharmacology (01-07-1996)
    “…Isosorbide dinitrate is one of the most commonly prescribed medications for the treatment of ischemic heart disease. It has been demonstrated to be ineffective…”
    Get more information
    Journal Article
  13. 13

    Effect of influenza vaccine on markers of inflammation and lipid profile by Tsai, Michael Y., Hanson, Naomi Q., Straka, Robert J., Hoke, Tracy R., Ordovas, Jose M., Peacock, James M., Arends, Valerie L., Arnett, Donna K.

    “…Despite wide use of the influenza vaccine, relatively little is known about its effect on the measurement of inflammatory markers. Because inflammatory markers…”
    Get full text
    Journal Article
  14. 14

    Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States by Straka, R J, Hansen, S R, Benson, S R, Walker, P F

    Published in Journal of clinical pharmacology (01-08-1996)
    “…Pharmacogenetics can be an important determinant of pharmacologic response. To learn more about interpopulation differences in drug metabolism between…”
    Get more information
    Journal Article
  15. 15
  16. 16

    Determination of dextromethorphan and its O-demethylated metabolite from urine by Marshall, P S, Straka, R J, Johnson, K

    Published in Therapeutic drug monitoring (01-10-1992)
    “…A high-performance liquid chromatography (HPLC) assay for the simultaneous quantitation of dextromethorphan and its O-demethylated metabolite dextrorphan from…”
    Get more information
    Journal Article
  17. 17

    Antihypertensive drug use in the long-term care facility: a pilot study and review of the literature by Fish, J T, Guay, D R, Straka, R J

    Published in Pharmacotherapy (01-11-1995)
    “…The overuse and cost of drugs in long-term care facilities are of significant concern. To quantify potential overuse of antihypertensive agents, we conducted a…”
    Get more information
    Journal Article
  18. 18

    QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature by Tschida, S J, Guay, D R, Straka, R J, Hoey, L L, Johanning, R, Vance-Bryan, K

    Published in Pharmacotherapy (01-07-1996)
    “…Intravenous erythromycin has recently been associated with significant QTc interval prolongation, torsades de pointes, and sudden cardiac death. The prolonged…”
    Get more information
    Journal Article
  19. 19

    Measurement of underivatized propranolol enantiomers in serum using a cellulose-tris(3,5-dimethylphenylcarbamate) high-performance liquid chromatographic (HPLC) chiral stationary phase by STRAKA, R. J, LALONDE, R. L, WAINER, I. W

    Published in Pharmaceutical research (01-03-1988)
    “…A commercially available high-performance liquid chromatographic (HPLC) chiral stationary phase (HPLC-CSP) has been used to measure serum levels of d- and…”
    Get full text
    Journal Article
  20. 20

    Improved selectivity of a high-performance liquid chromatography assay for debrisoquine and its 4-hydroxy metabolite from urine by Johnson, K A, Kolatkar, V, Straka, R J

    Published in Therapeutic drug monitoring (01-09-1990)
    “…Debrisoquine is an antihypertensive drug that displays polymorphic metabolism and has been used to determine hydroxylator status in human subjects. A…”
    Get more information
    Journal Article